Cart
sales@molnova.com
(Z)-FeCP-oxindole
CAS No. 1137967-28-2
(Z)-FeCP-oxindole( —— )
Catalog No. M33952 CAS No. 1137967-28-2
(Z)-FeCP-oxindole is a selective inhibitor of VEGFR2 with an IC50 of 200 nM for humans and demonstrates anticancer activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 29 | In Stock |
|
| 10MG | 49 | In Stock |
|
| 25MG | 93 | In Stock |
|
| 50MG | 148 | In Stock |
|
| 100MG | 226 | In Stock |
|
| 200MG | 318 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(Z)-FeCP-oxindole
-
NoteResearch use only, not for human use.
-
Brief Description(Z)-FeCP-oxindole is a selective inhibitor of VEGFR2 with an IC50 of 200 nM for humans and demonstrates anticancer activity.
-
Description(Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC50 value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC50 less than 1 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1137967-28-2
-
Formula Weight329.17
-
Molecular FormulaC19H15FeNO
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (151.90 mM; Ultrasonic )
-
SMILESC(\[C-]12[Fe+2]3456789([CH]1=[CH]3[CH]4=[CH]52)[CH-]%10[CH]6=[CH]7[CH]8=[CH]9%10)=C\%11/C=%12C(NC%11=O)=CC=CC%12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. John Spencer, et al. Synthesis and evaluation of metallocene containing methylidene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors. Metallomics. 2011 Jun;3(6):600-8.?
molnova catalog
related products
-
Lariciresinol
Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans. Dietary lariciresinol can attenuate mammary tumor growth and reduce blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.
-
DMH4
DMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 μM.
-
PKI-166
PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.
